Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000992792 | SCV001145336 | uncertain significance | not provided | 2019-06-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001051001 | SCV001215134 | uncertain significance | Spastic paraplegia | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with tryptophan at codon 1547 of the SACS protein (p.Arg1547Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs772907934, ExAC 0.008%). This variant has not been reported in the literature in individuals affected with SACS-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001784522 | SCV002026528 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001784522 | SCV002086272 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-03-01 | no assertion criteria provided | clinical testing |